EXTENDICARE INC (EXE.CA) Fundamental Analysis & Valuation
TSX:EXE • CA30224T8639
Current stock price
28.81 CAD
+0.47 (+1.66%)
Last:
This EXE.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. EXE.CA Profitability Analysis
1.1 Basic Checks
- In the past year EXE was profitable.
- In the past year EXE had a positive cash flow from operations.
- In the past 5 years EXE has always been profitable.
- EXE had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 9.06%, EXE belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
- With an excellent Return On Equity value of 25.89%, EXE belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 14.09%, EXE belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for EXE is significantly above the industry average of 6.48%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.06% | ||
| ROE | 25.89% | ||
| ROIC | 14.09% |
ROA(3y)8.19%
ROA(5y)6.95%
ROE(3y)41.67%
ROE(5y)41.08%
ROIC(3y)14.71%
ROIC(5y)10.79%
1.3 Margins
- With an excellent Profit Margin value of 5.82%, EXE belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
- In the last couple of years the Profit Margin of EXE has grown nicely.
- EXE has a better Operating Margin (8.35%) than 75.00% of its industry peers.
- In the last couple of years the Operating Margin of EXE has remained more or less at the same level.
- The Gross Margin of EXE (14.26%) is worse than 83.33% of its industry peers.
- EXE's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.35% | ||
| PM (TTM) | 5.82% | ||
| GM | 14.26% |
OM growth 3Y57.94%
OM growth 5Y0.49%
PM growth 3Y0.74%
PM growth 5Y4.46%
GM growth 3Y17.09%
GM growth 5Y-1.93%
2. EXE.CA Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), EXE is creating value.
- EXE has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, EXE has more shares outstanding
- Compared to 1 year ago, EXE has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 4.09 indicates that EXE is not in any danger for bankruptcy at the moment.
- EXE's Altman-Z score of 4.09 is amongst the best of the industry. EXE outperforms 83.33% of its industry peers.
- EXE has a debt to FCF ratio of 3.18. This is a good value and a sign of high solvency as EXE would need 3.18 years to pay back of all of its debts.
- EXE has a Debt to FCF ratio of 3.18. This is amongst the best in the industry. EXE outperforms 83.33% of its industry peers.
- A Debt/Equity ratio of 0.83 indicates that EXE is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.83, EXE perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 3.18 | ||
| Altman-Z | 4.09 |
ROIC/WACC1.89
WACC7.46%
2.3 Liquidity
- EXE has a Current Ratio of 1.37. This is a normal value and indicates that EXE is financially healthy and should not expect problems in meeting its short term obligations.
- EXE has a better Current ratio (1.37) than 91.67% of its industry peers.
- A Quick Ratio of 1.37 indicates that EXE should not have too much problems paying its short term obligations.
- EXE's Quick ratio of 1.37 is amongst the best of the industry. EXE outperforms 91.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.37 |
3. EXE.CA Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 40.99% over the past year.
- Measured over the past years, EXE shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.56% on average per year.
- EXE shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.25%.
- Measured over the past years, EXE shows a small growth in Revenue. The Revenue has been growing by 7.47% on average per year.
EPS 1Y (TTM)40.99%
EPS 3Y12.58%
EPS 5Y15.56%
EPS Q2Q%34.86%
Revenue 1Y (TTM)13.25%
Revenue growth 3Y10.77%
Revenue growth 5Y7.47%
Sales Q2Q%18%
3.2 Future
- EXE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.39% yearly.
- Based on estimates for the next years, EXE will show a quite strong growth in Revenue. The Revenue will grow by 13.52% on average per year.
EPS Next Y8.39%
EPS Next 2Y12.95%
EPS Next 3Y12.39%
EPS Next 5YN/A
Revenue Next Year32.28%
Revenue Next 2Y19.54%
Revenue Next 3Y13.52%
Revenue Next 5YN/A
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. EXE.CA Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 25.95, EXE can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Earnings ratio of EXE indicates a rather cheap valuation: EXE is cheaper than 83.33% of the companies listed in the same industry.
- EXE is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.91, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 25.24, which means the current valuation is very expensive for EXE.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of EXE indicates a somewhat cheap valuation: EXE is cheaper than 75.00% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.69, EXE is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.95 | ||
| Fwd PE | 25.24 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, EXE is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of EXE is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.25 | ||
| EV/EBITDA | 15.4 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates EXE does not grow enough to justify the current Price/Earnings ratio.
- EXE has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as EXE's earnings are expected to grow with 12.39% in the coming years.
PEG (NY)3.09
PEG (5Y)1.67
EPS Next 2Y12.95%
EPS Next 3Y12.39%
5. EXE.CA Dividend Analysis
5.1 Amount
- EXE has a Yearly Dividend Yield of 2.02%. Purely for dividend investing, there may be better candidates out there.
- Compared to an average industry Dividend Yield of 1.56, EXE pays a bit more dividend than its industry peers.
- EXE's Dividend Yield is comparable with the S&P500 average which is at 1.89.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.02% |
5.2 History
- The dividend of EXE has a limited annual growth rate of 0.28%.
- EXE has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)0.28%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- 43.14% of the earnings are spent on dividend by EXE. This is a bit on the high side, but may be sustainable.
- The dividend of EXE is growing, but earnings are growing more, so the dividend growth is sustainable.
DP43.14%
EPS Next 2Y12.95%
EPS Next 3Y12.39%
EXE.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:EXE (4/8/2026, 7:00:00 PM)
28.81
+0.47 (+1.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-26 2026-02-26
Earnings (Next)05-04 2026-05-04
Inst Owners23.28%
Inst Owner ChangeN/A
Ins Owners0.96%
Ins Owner ChangeN/A
Market Cap2.72B
Revenue(TTM)1.66B
Net Income(TTM)96.66M
Analysts78
Price Target28.52 (-1.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.02% |
Yearly Dividend0.47
Dividend Growth(5Y)0.28%
DP43.14%
Div Incr Years0
Div Non Decr Years0
Ex-Date03-31 2026-03-31 (0.0441)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.74%
PT rev (3m)16.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-3.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.85%
Revenue NY rev (3m)-2.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.95 | ||
| Fwd PE | 25.24 | ||
| P/S | 1.64 | ||
| P/FCF | 26.25 | ||
| P/OCF | 16.64 | ||
| P/B | 7.29 | ||
| P/tB | 15.28 | ||
| EV/EBITDA | 15.4 |
EPS(TTM)1.11
EY3.85%
EPS(NY)1.14
Fwd EY3.96%
FCF(TTM)1.1
FCFY3.81%
OCF(TTM)1.73
OCFY6.01%
SpS17.58
BVpS3.95
TBVpS1.89
PEG (NY)3.09
PEG (5Y)1.67
Graham Number9.94
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.06% | ||
| ROE | 25.89% | ||
| ROCE | 18.83% | ||
| ROIC | 14.09% | ||
| ROICexc | 26.71% | ||
| ROICexgc | 53.72% | ||
| OM | 8.35% | ||
| PM (TTM) | 5.82% | ||
| GM | 14.26% | ||
| FCFM | 6.24% |
ROA(3y)8.19%
ROA(5y)6.95%
ROE(3y)41.67%
ROE(5y)41.08%
ROIC(3y)14.71%
ROIC(5y)10.79%
ROICexc(3y)22.22%
ROICexc(5y)15.92%
ROICexgc(3y)39.32%
ROICexgc(5y)26.96%
ROCE(3y)19.66%
ROCE(5y)14.43%
ROICexgc growth 3Y88.69%
ROICexgc growth 5Y25.88%
ROICexc growth 3Y67.25%
ROICexc growth 5Y13.75%
OM growth 3Y57.94%
OM growth 5Y0.49%
PM growth 3Y0.74%
PM growth 5Y4.46%
GM growth 3Y17.09%
GM growth 5Y-1.93%
F-Score6
Asset Turnover1.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 3.18 | ||
| Debt/EBITDA | 1.77 | ||
| Cap/Depr | 162.15% | ||
| Cap/Sales | 3.61% | ||
| Interest Coverage | 12.73 | ||
| Cash Conversion | 93.15% | ||
| Profit Quality | 107.28% | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 4.09 |
F-Score6
WACC7.46%
ROIC/WACC1.89
Cap/Depr(3y)229.86%
Cap/Depr(5y)237.24%
Cap/Sales(3y)5.46%
Cap/Sales(5y)6.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.99%
EPS 3Y12.58%
EPS 5Y15.56%
EPS Q2Q%34.86%
EPS Next Y8.39%
EPS Next 2Y12.95%
EPS Next 3Y12.39%
EPS Next 5YN/A
Revenue 1Y (TTM)13.25%
Revenue growth 3Y10.77%
Revenue growth 5Y7.47%
Sales Q2Q%18%
Revenue Next Year32.28%
Revenue Next 2Y19.54%
Revenue Next 3Y13.52%
Revenue Next 5YN/A
EBIT growth 1Y24.69%
EBIT growth 3Y74.95%
EBIT growth 5Y7.99%
EBIT Next Year42.01%
EBIT Next 3Y19.17%
EBIT Next 5YN/A
FCF growth 1Y1.97%
FCF growth 3YN/A
FCF growth 5Y3.29%
OCF growth 1Y13.89%
OCF growth 3Y18.28%
OCF growth 5Y6.16%
EXTENDICARE INC / EXE.CA Fundamental Analysis FAQ
What is the fundamental rating for EXE stock?
ChartMill assigns a fundamental rating of 6 / 10 to EXE.CA.
What is the valuation status for EXE stock?
ChartMill assigns a valuation rating of 4 / 10 to EXTENDICARE INC (EXE.CA). This can be considered as Fairly Valued.
How profitable is EXTENDICARE INC (EXE.CA) stock?
EXTENDICARE INC (EXE.CA) has a profitability rating of 7 / 10.
What is the valuation of EXTENDICARE INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for EXTENDICARE INC (EXE.CA) is 25.95 and the Price/Book (PB) ratio is 7.29.
How financially healthy is EXTENDICARE INC?
The financial health rating of EXTENDICARE INC (EXE.CA) is 7 / 10.